Meiji Yasuda Asset Management’s AbbVie ABBV Stock Holding History

Meiji Yasuda Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.7M	Sell	131,878 -34,794	-21%	-$7.72M	1.43%	8
2025 Q4	$38.1M	Sell	166,672 -864	-0.5%	-$197K	1.83%	6
2025 Q3	$38.8M	Sell	167,536 -212	-0.1%	-$43.2K	1.85%	6
2025 Q2	$31.1M	Sell	167,748 -15,604	-9%	-$2.9M	1.54%	7
2025 Q1	$38.4M	Sell	183,352 -31,981	-15%	-$6.22M	1.55%	7
2024 Q4	$38.3M	Buy	215,333 +19,051	+10%	+$3.5M	1.46%	7
2024 Q3	$38.8M	Buy	196,282 +7,027	+4%	+$1.31M	1.48%	7
2024 Q2	$32.5M	Buy	189,255 +14,220	+8%	+$2.36M	1.32%	8
2024 Q1	$31.9M	Sell	175,035 -10,579	-6%	-$1.82M	1.36%	7
2023 Q4	$28.8M	Sell	185,614 -977	-0.5%	-$142K	1.29%	7
2023 Q3	$27.8M	Buy	186,591 +15,578	+9%	+$2.29M	1.3%	8
2023 Q2	$23M	Sell	171,013 -2,516	-1%	-$369K	1.15%	10
2023 Q1	$27.7M	Sell	173,529 -34,776	-17%	-$5.32M	1.43%	5
2022 Q4	$33.7K	Buy	208,305 +46,728	+29%	+$7.16M	1.61%	5
2022 Q3	$21.7M	Buy	161,577 +31,598	+24%	+$4.53M	1.27%	7
2022 Q2	$19.9M	Buy	129,979 +3,687	+3%	+$563K	1.16%	9
2022 Q1	$20.5M	Buy	126,292 +35,913	+40%	+$5.22M	1.12%	8
2021 Q4	$12.2M	Sell	90,379 -270	-0.3%	-$31.9K	0.76%	27
2021 Q3	$9.78M	Sell	90,649 -92,265	-50%	-$10.5M	0.69%	28
2021 Q2	$20.6M	Buy	182,914 +87,774	+92%	+$9.89M	0.98%	19
2021 Q1	$10.3M	Buy	95,140 +33,784	+55%	+$3.61M	0.76%	24
2020 Q4	$6.57M	Buy	61,356 +3,277	+6%	+$315K	0.65%	33
2020 Q3	$5.09M	Sell	58,079 -15,431	-21%	-$1.45M	0.56%	41
2020 Q2	$7.22M	Buy	73,510 +15,622	+27%	+$1.38M	0.68%	32
2020 Q1	$4.41M	Sell	57,888 -12,748	-18%	-$1.09M	0.83%	32
2019 Q4	$6.25M	Sell	70,636 -10,930	-13%	-$907K	0.52%	48
2019 Q3	$6.18M	Buy	81,566 +7,604	+10%	+$521K	0.5%	50
2019 Q2	$5.38M	Sell	73,962 -5,342	-7%	-$420K	0.45%	59
2019 Q1	$6.39M	Sell	79,304 -1,660	-2%	-$136K	0.54%	49
2018 Q4	$7.46M	Sell	80,964 -793	-1%	-$69.7K	0.7%	32
2018 Q3	$7.73M	Buy	81,757 +980	+1%	+$92.9K	0.63%	35
2018 Q2	$7.48M	Buy	80,777 +7,110	+10%	+$694K	0.67%	32
2018 Q1	$6.97M	Buy	73,667 +441	+0.6%	+$48.4K	0.66%	32
2017 Q4	$7.08M	Sell	73,226 -4,678	-6%	-$441K	0.67%	33
2017 Q3	$6.92M	Sell	77,904 -1,050	-1%	-$79.9K	0.68%	30
2017 Q2	$5.72M	Buy	78,954 +2,310	+3%	+$155K	0.59%	41
2017 Q1	$4.99M	Sell	76,644 -3,248	-4%	-$204K	0.53%	46
2016 Q4	$5M	Buy	79,892 +2,077	+3%	+$127K	0.56%	45
2016 Q3	$4.91M	Buy	77,815 +7,201	+10%	+$466K	0.58%	41
2016 Q2	$4.37M	Buy	70,614 +10,203	+17%	+$622K	0.63%	39
2016 Q1	$3.45M	Buy	60,411 +6,160	+11%	+$343K	0.78%	36
2015 Q4	$3.21M	Sell	54,251 -3,520	-6%	-$203K	0.73%	40
2015 Q3	$3.14M	Buy	57,771 +5,627	+11%	+$366K	0.77%	37
2015 Q2	$3.5M	Sell	52,144 -677	-1%	-$44.2K	0.82%	32
2015 Q1	$3.09M	Sell	52,821 -765	-1%	-$46.2K	0.75%	38
2014 Q4	$3.51M	Sell	53,586 -779	-1%	-$49.1K	0.84%	32
2014 Q3	$3.14M	Sell	54,365 -9,327	-15%	-$518K	0.74%	38
2014 Q2	$3.6M	Buy	63,692 +872	+1%	+$45.7K	0.74%	44
2014 Q1	$3.23M	Sell	62,820 -13,145	-17%	-$664K	0.7%	49
2013 Q4	$4.01M	Sell	75,965 -1,997	-3%	-$98.1K	0.85%	28
2013 Q3	$3.49M	Sell	77,962 -1,490	-2%	-$66K	0.79%	38
2013 Q2	$3.35M	Buy	+79,452	New	+$3.47M	0.79%	38

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Meiji Yasuda Asset Management's ABBV Position: Q1 2026 in Review

Meiji Yasuda Asset Management reduced its AbbVie (ABBV) stake by 21% in Q1 2026, selling an estimated $7.72M and leaving 131,878 shares worth $28.7M. The position accounts for 1.43% of the portfolio, ranked #8.

Meiji Yasuda Asset Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $38.8M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Meiji Yasuda Asset Management held 131,878 shares of AbbVie worth $28.7M as of Q1 2026.
Meiji Yasuda Asset Management sold 34,794 AbbVie shares in Q1 2026, an estimated $7.72M.
AbbVie made up 1.43% of Meiji Yasuda Asset Management's portfolio in Q1 2026, its #8 holding.
Meiji Yasuda Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Meiji Yasuda Asset Management's AbbVie position peaked at $38.8M in Q3 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Meiji Yasuda Asset Management's 13F filing for Q1 2026, filed 14 May 2026.